GILD

Gilead is a high-quality, cash-generative franchise rather than a grower. FY2025 delivered $29.4B revenue (+2.4% YoY) at a 34.0% operating margin, 28.9% net margin and a 37.5% ROE — elite profitability. But the eye-popping headlines (net income +1672.9% to $8.51B, diluted EPS +1684.2% to $6.78) are a base effect off a depressed FY2024 that earned just $480M; across the five-year history revenue has been essentially flat ($27.1B–$29.4B). So the durable story is stability and capital return, not top-line expansion.

The filing materially de-risks the bull case's biggest worry. Settlements with Lupin, Cipla and Laurus push the earliest U.S. generic Biktarvy launch to April 1, 2036 — more than two years beyond the prior December 2033 loss-of-exclusivity assumption — protecting the core cash cow. Alongside that, the long-acting HIV engine is real: Yeztugo (lenacapavir) twice-yearly PrEP won FDA and EC approval, a 'strong recommendation' in new CDC guidelines, and a PEPFAR partnership to reach up to two million people over three years, while ARTISTRY-1/2 showed BIC/LEN non-inferior to Biktarvy. These are genuine forward catalysts on top of a 34%-margin base.